Objectives To compare efficacy, survival outcome and prognostic factors of conventional transarterial chemoembolisation (cTACE), drug-eluting beads TACE (DEB-TACE) and yttrium-90 radioembolisation (Y90) for the treatment of liver metastases from gastroenteropancreatic (GEP) neuroendocrine tumours (NELM). Methods This retrospective analysis included 192 patients (58.6 years mean age, 56% men) with NELM treated with cTACE (N = 122), DEB-TACE (N = 26) or Y90 (N = 44) between 2000 and 2014. Radiologic response to therapy was assessed according to Response Evaluation Criteria in Solid Tumours (RECIST) and World Health Organization (WHO) criteria using periprocedural MR imaging. Survival analysis included propensity score analysis (PSA), median overall survival (MOS), hepatic progression-free survival, KaplanMeier using log-rank test and the uni-and multivariate Cox proportional hazards model (MVA). Results MOS of the entire study population was 28.8 months.
Introduction
Neuroendocrine tumours (NETs) comprise a heterogeneous group of relatively rare malignant tumour entities that usually appear as slow-growing neoplasms. NETs originating from gastroenteropancreatic (GEP) tissue demonstrate a predisposition to liver metastases (NET-liver metastases [NELM] ) associated with symptom-related severe impairment of the quality of life and reduced life expectancy. In 46-93% of cases, patients with NET present with NELM at initial diagnosis [1] [2] [3] . At this stage, curative treatment is only possible i n 10 -20% of cases [ 3 ] . Gastroenteropancreatic NELM can originate from pancreatic islet cells (pancreatic (p)NET) or neuroendocrine cells (carcinoid) [4] . As secreted hormones are mainly inactivated by the liver, NELM often remain asymptomatic until the primary tumour has metastasized to the liver with impairment of liver function [5] . In this setting, on the basis of the arterial hypervascularity and the preferentially arterial blood supply of NELM, palliative options include image-guided intra-arterial therapies (IAT) such as bland transarterial embolization (TAE), conventional transarterial chemoembolisation (cTACE), drug-eluting beads TACE (DEB-TACE) and yttrium-90 radioembolisation (Y90) [6] , which improve the 5-year survival rate up to 50-80% [7, 8] .
Multiple studies report evidence in support of the beneficial effects of TAE, cTACE, DEB-TACE or Y90 in patients with unresectable NELM. However, no comparative analysis of the efficacy of the three commonly used IAT options (cTACE vs. DEB-TACE vs. Y90) exists. Thus, no conclusive recommendation can be drawn for a favourable choice of IAT. To date, trials that compare the efficacy of IAT modalities have not revealed significant differences in overall survival (OS) [3] .
The objective of our study was to compare efficacy, survival outcome and prognostic factors of cTACE, DEB-TACE and Y90 for the treatment of gastroenteropancreatic NELM. Specifically, this was done with regard to radiologic response (RR), hepatic progression-free survival (HPFS) and OS to identify favourable treatment options and prognostic factors in this setting.
Materials and methods

Study cohort
This retrospective single-institution study was compliant with the Health Insurance Portability and Accountability Act (HIPAA) and approved by the institutional review board. Informed consent was waived.
Electronic medical records, pathology reports, retrospective pathological review and grading of samples, and imaging studies were used to collect demographic, pathological, treatment and outcome data of the patients. 
Intra-arterial therapy
Histopathological NET type (pNET, carcinoid) determined by the World Health Organization (WHO) classification system was obtained from the in-house pathology service records [9, 10] . Patient cases with missing grading records were retrieved and regraded according to the WHO standard. Samples originated from resected primary tumours or-for cases with unknown primary or unresectable disease-from biopsy specimen originated from the liver before the initial cycle of intra-arterial therapy [11] . Both functional as well as non-functional pancreatic NET were labelled as pNET. The choice of IAT (cTACE, DEB-TACE or Y90) was made in concordance with the National Comprehensive Cancer Network guidelines for NETs during a multidisciplinary liver tumour board which included hepatologists, medical oncologists, liver surgeons, pathologists and interventional radiologists; decision criteria are further described in the Supplementary Material [12, 13] .
In general, cTACE, DEB-TACE or Y90 was performed on NELM patients with unresectable hepatic-dominant disease that was symptomatic or progressive in patients that qualified with an Eastern Cooperative Oncology Group score (ECOG) 0-2, and adequate hepatic, renal and haematological function.
For all patients, only one lobe of the liver was subjected to embolization during each treatment session. Additional sessions of cTACE, DEB-TACE or Y90 were considered when palliation of symptoms or local tumour control was not achieved by the initial therapy cycle.
All IAT procedures were performed by the same interventional radiologist (J.F.G. with meanwhile 19 years of experience in hepatic interventions) using a standardized approach in accordance with our institutional protocols [14] . A brief summary of each protocol is described in the Supplementary Material.
Imaging data evaluation
Patients underwent baseline and follow-up (MR or CT) imaging within 3-4 weeks before and after the initial cTACE, DEB-TACE or Y90. Additional follow-up abdominal (MRI or CT) scans were obtained 3-4 months after the first embolization, then every 4-6 months for the first 2 years, and annually thereafter. A brief summary of the imaging protocol (MR, CT) is described in the Supplementary Material. 
Adverse events
Procedure-related adverse events were assessed within the framework of direct postprocedural care and during clinical follow-up appointments. Recorded data was assessed retrospectively and reported for patients with complete data.
Statistical analysis
OS was defined as the period between the initial embolization procedure and the date of death from any cause or last followup for patients who remained alive at the time of last followup. HPFS was defined as the period between the date of the initial embolization and the date of progression for patients who displayed radiologic evidence of disease progression in the liver or the date of death or last follow-up for patients who did not progress. As a result of the retrospective nature of our study, randomization was not possible and so propensity score analysis (PSA) was performed to compensate for selection bias and cohort heterogeneities [15] . After considering different methods for PSA, such as matching, subclassification or full matching, we chose the inverse probability of treatment weighting because it allowed us to use all patients available in a relatively small study cohort while minimising cohort size Fig. 1 Exclusion criteria flow chart. cTACE conventional transarterial chemoembolisation, DEB-TACE drug-eluting beads TACE, Y90 yttrium-90 radioembolisation differences [16] [17] [18] . A brief summary of the PSA is described in the Supplementary Material.
PSA-adjusted univariate Cox proportional hazards regression models (UVA) were set up to evaluate the predictive value of each covered factor. PSA-adjusted multivariate Cox models (MVA) were created to assess the prognostic effects of the inspected factors simultaneously. Only those variables showing p < .05 in the UVA and the treatment variables (cTACE vs. DEB-TACE vs. Y90) were further investigated in the MVA. The MOS was calculated using the PSA-adjusted Kaplan-Meier method. The PSA-adjusted log-rank test was used to compare cumulative survival between the groups [19] . As recommended by the literature the PSA can only be performed between two groups, thereby ensuring a statistically robust conclusion [17] . Therefore, to compare the three treatment arms, we conducted three pairwise comparison analyses: (1) cTACE cohort vs. DEB-TACE cohort, (2) cTACE cohort vs. Y90 cohort and (3) DEB-TACE cohort vs. Y90 cohort. The probability of CR, PR and MR was determined by UVA and MVA logistic regression techniques. A HosmerLemeshow goodness-of-fit test was assessed for each model. Fisher's exact test was performed to compare the differences in adverse events between the treatment modalities.
Statistical significance was defined as p < .05. Statistical tests were performed using SPSS software (IBM SPSS Statistics, version 23, 2015, IBM Corp, Armonk, NY, USA). The PSA was applied using R 3.2.3 (R Core Team, 2015, Vienna, Austria) including the addin R package twang [20, 21] .
Results
Patient characteristics
A total of 192 patients were included in the final data analysis, which comprised N = 122, N = 26 and N = 44 patients who underwent cTACE, DEB-TACE or Y90, respectively. The MOS of the study cohort was 28.8 months and by the endof-observation date (18 May 2014), during a median followup time of 75.6 months a total of 74.5% (143/192) patients were deceased. Of 192 patients, 125 were identified with carcinoid (65.1%) and 67 with pNET (34.9%). Fifty-seven patients (29.7%) had a tumour burden (TB) >50%. The mean number of IAT sessions per patient was 2.9, 2.1 and 1.7 for cTACE, DEB-TACE and Y90, respectively. Patient demographics, tumour characteristics and treatment details for patient groups are summarised in Table 1 . Applying PSA served to minimize selection bias for the choice of treatment, and to achieve a balance among covariates. We chose those covariates which according to the reviewed literature have an impact on survival outcome (ECOG, liver tumour resection with curative intention/radiofrequency ablation (Rx/RFA), primary tumour resection, chemotherapy, liver metastases debulking, TB >50%, extrahepatic metastases), and balance was achieved (Fig. 2) [4, [22] [23] [24] [25] [26] .
Overall survival
Prior to PSA, the MOS after cTACE, DEB-TACE and Y90 was 33.8, 21.7, and 23.6 months, respectively. Additionally, the overall cumulative 1-year, 2-year and 5-year OS rates were 80.9%, 60.4% and 28.2% after cTACE, respectively; 73.0%, 38.3% and 10.3% after DEB-TACE, respectively; and 71.2%, 49.4% and 18.5% after Y90, respectively. After PSA, patients who underwent cTACE lived significantly longer than patients who received DEB-TACE or Y90 (cTACE vs. DEB-TACE, 33.8 vs. 23.4 months, p = .04; cTACE vs. Y90, 34.0 vs. 22.9 months, p = .032). A comparison of DEB-TACE vs. Y90 did not reveal statistically significant differences in MOS (p = .86) (Fig. 3a-c) .
In the comparison of cTACE vs. DEB-TACE, cTACE corresponded to prolonged OS in the MVA (p < .01, HR 0.55). Further, in the comparison of cTACE vs. Y90, cTACE was predictive for improved OS in the MVA (p = .02, HR 0.61).
In the entire study cohort, age (p = .01, HR 1.81), TB >50% (p < .01, HR 1.93) and presence of extrahepatic metastases (p < 0.01, HR 1.63) were identified as independent predictors for reduced OS (Table 2) .
Hepatic progression-free survival
A total of 149 patients with available baseline and follow-up MR imaging were considered for HPFS analysis comprising 90, 23 and 36 patients who underwent cTACE, DEB-TACE or Y90, respectively. In the PSA, patients who received cTACE showed a prolonged HPFS compared to patients who received Y90 (21.6 vs. 11.2 months, respectively, p = .03), whereas in the comparison of cTACE vs. DEB-TACE (20.1 vs. 14.6 months, respectively, p = .14) and Y90 vs. DEB-TACE (11.2 vs. 13.3 months, respectively, p = .72) there was no significant difference in HPFS. In the comparison of cTACE and Y90, cTACE was predictive for improved HPFS in the PSadjusted MVA (p = .03, HR 0.57) ( Supplementary Fig. 1a-c) .
Radiologic response
The cohort for the HPFS analysis was also considered for RR analysis. According to the WHO classification, none of these patients demonstrated CR whereas PR was observed in 26, MR in 44, SD in 76 and PD in 3 patients (Table 3) . Across all groups, no statistically significant difference between responder and non-responder was achieved according to WHO criteria. As for RECIST, 0, 4, 136 and 9 patients were identified with CR, PR, SD and PD, respectively. DEB-TACE treatment was significantly correlated with 1.33 times higher RR than Y90 (MVA, p = .03) (Supplementary Table 4) .
Adverse events
Overall, adverse events were recorded in 164 (85.4%) patients with rates of 85.2%, 88.5% and 84.1% after cTACE, DEB-TACE and Y90, respectively. Common adverse events in all treatment cohorts included diarrhoea (33.3%), abdominal pain (29.6%) and flushing (26.5%) ( Table 4 ).
Discussion
Our main finding is that patients with NELM treated with cTACE showed clear OS benefits as compared to DEB- RFA radio frequency ablation, Rx tumour resection with curative intention, pNET pancreatic neuroendocrine tumour, IAT intra-arterial therapy, CI confidence interval, cTACE conventional transarterial chemoembolisation, DEB-TACE drug-eluting beads TACE, Y90 yttrium-90 radioembolisation a Extrahepatic metastases (lung, bone, soft tissue, retroperitoneal, gastrointestinal system, lymph node) TACE (33.8 vs. 23.4 months, p = .04) and Y90 (34.0 vs. 22.9 months, p = .032). Importantly, after adjusting for confounders in the MVA using the propensity score methodology, the difference in survival remained statistically significant. Our study is among very few published datasets that compare clinical outcomes between different IAT modalities in NELMs and the first to specifically compare the three commonly used locoregional therapeutic modalities (cTACE vs. DEB-TACE vs. Y90) in the largest ever reported cohort of such patients. Although retrospective in nature, our study uses a comprehensive statistical analysis to correct for potential selection bias, thus providing for relatively homogeneous groups of patients. Currently, no clinical trial is completed that would address the questions raised and answered by our data analysis and only one clinical trial is currently ongoing (NCT02724540) that may potentially answer some of the challenging IAT-related issues with respect to decision-making in NELMs. As such, our results evidently support the preferential use of Lipiodol-based cTACE over other intra-arterial therapies not only by a statistically significant but rather by a substantial margin with respect to OS benefits.
The vast majority of currently available studies investigate TAE and cTACE as treatment options for patients with unresectable NELM. For example, as exhibited by Ruutiainen et al., MOS was 39 months and 44 months for patients who underwent TAE or cTACE, respectively [27] . Furthermore, a large-scale study by Dong et al. that included (N = 123) patients who received cTACE for NELM reported a 5-year cumulative OS rate of 36% compared to 28.2% in our study [28] . If compared further, all of the aforementioned studies achieved slightly better OS outcomes as compared with our own cohort. This can be explained by a substantially higher rate of patients with extrahepatic metastases and TB >50% in our cohort which reflects our institutional approach to treat patients with late-stage disease. This is in agreement with available data, which suggests a significantly higher mortality in patients with a TB >50% [29] . With respect to extrahepatic metastases, Gupta et al. reported a substantial negative impact on survival outcomes of extrahepatic bone and softtissue metastases both for carcinoids and pNET [4] . To assess the balance in baseline covariates (ECOG, liver tumour resection with curative intention/radiofrequency ablation (Rx/RFA), primary tumour resection, chemotherapy, liver metastases debulking, tumour burden >50%, extrahepatic metastases) the standardised mean difference (SMD) has been used. Figure 2 shows line plots of SMD before and after weighting. These plots display the effect of weights on the magnitude of differences between the treatment cohorts on each pretreatment covariate. A recommended threshold value for balance in the covariates is 0.2. As in these plots for all included covariates SMD <0.2 balance has been achieved by means of PSA. ECOG Eastern Cooperative Oncology Group score, SMD standardized mean difference, PSA propensity score analysis Initially, DEB-TACE seemed to emerge as an improvement over cTACE in the scope of treating patients with primary liver cancer (hepatocellular carcinoma, HCC) [14, 30] . DEB-TACE was demonstrated to allow for a better toxicity profile primarily owing to improved targeted delivery of the chemotherapy payload to the liver [31] . Thus, an auspicious impact on OS in treatment of NELM disease was also expected [14, [32] [33] [34] [35] . Yet, initial outcome reports for DEB-TACE in patients with NELM were disappointing, and in some cases significant toxicities, such as a higher incidence of biliary injury, occurred which required a modification of the protocol [36, 37] . As reported previously, the MOS for patients after receiving cTACE can range from Fig. 3 a Kaplan-Meier curves demonstrating survival of cTACE vs. DEB-TACE cohort after propensity score weighting. These PSAadjusted Kaplan-Meier curves for overall survival were calculated according to IAT modality, cTACE and DEB-TACE. After PSA the MOS of patients who underwent cTACE was significantly longer compared to the MOS of patients who underwent DEB-TACE (33.8 vs. 23.4 months, respectively, p = 0.04). b Kaplan-Meier curves demonstrating survival of cTACE vs. Y90 cohort after propensity score weighting. These PSA-adjusted Kaplan-Meier curves for overall survival were calculated according to IAT modality, cTACE and Y90. After PSA the MOS of patients who underwent cTACE was significantly longer compared to the MOS of those who underwent Y90 (34.0 vs. 22.9 months, respectively, p = 0.032). c Kaplan-Meier curves demonstrating survival of DEB-TACE vs. Y90 cohort after propensity score weighting. These PSA-adjusted Kaplan-Meier curves for overall survival were calculated according to IAT modality, DEB-TACE and Y90. After PSA, there was no statistically significant difference in OS between DEB-TACE and Y90 (22.9 vs 23.6 months, respectively, p = 0.86). PSA propensity score analysis, IAT intra-arterial therapy, MOS median overall survival, cTACE conventional transarterial chemoembolisation, Y90 yttrium-90 radioembolisation 24 to 44 months [27, 38] . Our outcome report is among the first to provide survival data for DEB-TACE in a sizable cohort of NELM patients. When compared with cTACE, our findings unequivocally confirm the survival benefits of the Lipiodol-based protocol. When taking into account that no differences between both TACE options were observed with respect to RR, HPFS and incidence of adverse events, our results support the use of cTACE in patients with NELM when given the choice between Lipiodol-based and DEB-based protocols.
Several recent studies promote Y90 as a potential alternative to TAE/cTACE in the treatment of patients with NELM [39] . Advantages associated with Y90 treatment include lower incidence rates of adverse events, such as postembolization syndrome, high RR and lower retreatment rates compared to cTACE, which is usually applied in repeated sessions. The majority of current studies compare Y90 to cTACE/TAE in terms of RR and symptomatic improvements with no data available with respect to survival outcomes [39] . Two recent studies by Rhee et al. and Kennedy et al. showed substantial disagreement with respect to MOS after Y90 in patients with NELM, ranging from 22 to 70 months [39, 40] . Our analysis demonstrates significant and substantial OS and HPFS benefits for patients who underwent cTACE as compared to those who were treated with Y90. This result remained significant upon elimination of selection bias using the PSA (MOS, 34.0 vs. 22.9 months, p = .032; HPFS 21.6 vs. 11.2 months, p = .03) as well as after adjusting for confounders in the MVA. In addition, cTACE and Y90 showed similar incidence rates of adverse events. An important point which should be considered with respect to this outcome analysis is the number of embolization sessions applied in each group. Because of inherent and well-known methodological limitations, the total number of Y90 therapy sessions is usually limited to two injections when treating in a lobar fashion. As cTACE treatment allows for additional embolization, multiple sessions can be performed in case of insufficient RR or new lesions upon completion of the initial therapy cycle [41] . In our cohort, all patients with therapy crossover were initially excluded with the goal of reducing potential bias. Thus, a slightly higher number of sessions per patient has been recorded for cTACE than for Y90. Although clear benefits of cTACE over Y90 were evident without therapy crossover, a true advantage might arise from sequential Y90 and cTACE therapy in patients with slow-growing NELM.
As for the comparison of Y90 and DEB-TACE, both techniques demonstrated a similar effect on OS and were equally safe. However, DEB-TACE corresponded to improved RR (MVA, p = .03). As demonstrated by Whitney et al., an exceptional RR (CR + PR) of 100% was attained by Y90 and DEB-TACE treatment after 3 months. However, in a 12-month follow-up, RR in the Y90 group was significantly lower than in the DEB-TACE group. Thus, patients who underwent Y90 were initially salvaged with repeated DEB-TACE treatment, which again underlines the potentially tremendous opportunities of the sequential crossover therapy option [34] .
There were several limitations to our study. First, because of the retrospective design and the non-randomized cohorts, there was a limited pool of patients and a correspondingly restricted statistical analysis. However, the limited number of patients with NELM mirrors the rarity of the investigated disease. Furthermore, possible confounders and selection bias were considered and minimized by PSA, as discussed previously. Most importantly, our study represents a longitudinal retrospective analysis of data collected over a period of almost 14 years. The last decade has seen an unparalleled growth and evolution of embolization and imaging technologies as well as the introduction of multiple new systemic and targeted therapies for neuroendocrine tumours. Taken together, all of these factors may have influenced PFS and OS of our patients and thus introduced a substantial bias into our analysis. Yet, given the lack of prospectively collected data, such retrospective data analyses represent the only currently available and much needed instrument to identify trends and design prospective trials.
Conclusion
Our propensity score analysis suggests the superiority of cTACE over DEB-TACE and Y90 with respect to overall survival among patients with unresectable NELM. In light of our findings and because of the lack of prospectively collected data from randomized controlled trials, it can be cautiously suggested that cTACE may evolve as the primary intraarterial therapy option in patients with unresectable NELM until proven otherwise.
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